Nosium Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Daniel Ehdin

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Recent updates

CEO

Daniel Ehdin

no data

Tenure

Mr. Daniel Ehdin serves as Chief Executive Officer and Director of Nosium AB (publ) (formerly known as Scandinavian Health Innovations AB (publ)) (formerly known as Dr Sannas AB (publ)).

Nosium Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

CEO & Director recently bought kr51k worth of stock

No independent directors

CEO & Director recently sold kr1m worth of stock

No independent directors

CEO & Director recently sold kr110k worth of stock

Recent updates

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

New minor risk - Financial data availability

CEO & Director recently bought kr51k worth of stock

New major risk - Share price stability

No independent directors

Second quarter 2022 earnings released

CEO & Director recently sold kr1m worth of stock

First quarter 2022 earnings released

No independent directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released

CEO & Director recently sold kr110k worth of stock

Second quarter 2021 earnings released

First quarter 2021 earnings released

New 90-day low: kr8.90

Full year 2020 earnings released: kr1.38 loss per share (vs kr0.35 loss in FY 2019)

Scandinavian Health Innovations AB (publ) (NGM:SHI B) acquired Brandtics AB for SEK 18.5 million.

Scandinavian Health Innovations AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.6 million.

New 90-day high - kr12.00

CEO

Tenure